Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective [Practice Report]

Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective Skip to main page content

HOME CURRENT ISSUE PAST ISSUES SUPPLEMENTS REPRINTS ALERTS KEYWORDS GO Advanced Search ? Advertisement
Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective Julian P. Casciano?, Zenobia Dotiwala, Robert Kemp, Chenghui Li, Jennifer Cai and Ronald Preblick

Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ. Address correspondence to Mr. Casciano (juliancasciano{at}emaxhealth.net). Abstract Purpose An analysis of resource utilization and hospital costs associated with recurrent venous thromboembolism (VTE) is presented.

Methods A retrospective cohort analysis was conducted using a large U.S. hospital database. Patients with VTE-related hospitalization events during the period January–December 2010 were identified; data collection extended for up to 12 months after the index event. Postdischarge hospital resource use and total costs were compared in cohorts of patients with and without recurrent VTE. Regression analysis was performed to compare hospital costs and length of stay (LOS) during initial and subsequent VTE encounters.

Results Among the study population of 43,734 patients, 4% had postdischarge VTE-related events during the data collection period. The median and mean ? S.D. times to VTE recurrence were 48 days and 98 ? 106 days, respectively. Patients with recurrent VTE had more all-cause hospitalizations than those without recurrent VTE (mean ? S.D., 1.07 ? 0.96 versus 0.15 ? 0.53; p < 0.0001), more all-cause emergency room visits (mean ? S.D., 0.31 ? 0.66 versus 0.05 ? 0.31; p < 0.0001), and greater total costs (mean ? S.D., $28,353 ? $39,624 versus $17,712 ? $33,461; p < 0.0001). Relative to initial VTE admissions, admissions for recurrent VTE were, on average, associated with a 14% longer LOS (p = 0.0002) and a 22% higher total cost (p < 0.001).

Conclusion Patients with recurrent VTE used more hospital resources than those without recurrent VTE. Readmissions for VTE were significantly longer and more costly than index encounters.

Copyright ? 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved. CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

? Previous | Next Article ? Table of Contents This Article doi: 10.2146/ajhp140204 American Journal of Health-System Pharmacy February 15, 2015 vol. 72 no. 4 291-300 ? Abstract Full Text Full Text (PDF) Classifications Print Content Practice Report Services Email this article to a colleague Alert me when this article is cited Alert me if a correction is posted Alert me when eLetters are published Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Download to citation manager eLetters Submit an eLetter No eLetters published Citing Articles Load citing article information Google Scholar Articles by Casciano, J. P. Articles by Preblick, R. PubMed PubMed citation Articles by Casciano, J. P. Articles by Preblick, R. Related Content Load related web page information Social Bookmarking CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

Current Issue February 15, 2015, 72 (4) Alert me to new issues of American Journal of Health-System Pharmacy From the Cover RhOD immune globulin products for prevention of alloimmunization during pregnancy Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective Comparative analytics of infusion pump data across multiple hospital systems ABOUT AJHP SUBSCRIPTIONS FOR AUTHORS/REVIEWERS PERMISSION REQUESTS ADVERTISING EMAIL ALERTS (FREE) RSS FEEDS (FREE) HELP CONTACT US/FEEDBACK American Society of Health System Pharmacists Learning Center (CE) Store Meetings & Conferences ASHP Foundation MOST READ ARTICLES (Last 30 Days) Clinical practice guidelines for antimicrobial prophylaxis in surgery Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists How to write a patient case report Treatment of poisoning caused by {beta}-adrenergic and calcium-channel blockers ? View all Most Read articles Advertisement ? 2015 by the American Society of Health-System Pharmacists. Terms of Use | Copyright Online ISSN: 1535-2900 Print ISSN: 1079-2082

View the original article here